Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Svb Leerink boosted their Q3 2019 earnings per share estimates for Aurinia Pharmaceuticals in a report issued on Wednesday, August 7th, according to Zacks Investment Research. Svb Leerink analyst J. Schwartz now expects that the company will post earnings of ($0.25) per share for the quarter, up from their prior forecast of ($0.27). Svb Leerink also issued estimates for Aurinia Pharmaceuticals’ Q4 2019 earnings at ($0.29) EPS, FY2019 earnings at ($0.96) EPS, FY2020 earnings at ($1.45) EPS and FY2021 earnings at ($0.72) EPS.
Aurinia Pharmaceuticals stock opened at C$7.50 on Friday. The business’s 50-day simple moving average is C$8.19 and its 200 day simple moving average is C$8.48. The stock has a market cap of $714.15 million and a price-to-earnings ratio of -10.81. Aurinia Pharmaceuticals has a 12-month low of C$6.61 and a 12-month high of C$10.47. The company has a quick ratio of 18.05, a current ratio of 18.98 and a debt-to-equity ratio of 0.33.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.